GEN News Highlights

Qiagen and Center for Molecular Medicine Team Up to Identify Breast Cancer Diagnostic Markers

(Page
1
of
1)

The Center for Molecular Medicine (CMM) and Qiagen are collaborating to discover molecular biomarkers to help with diagnosing breast cancer and other women's health issues.

Qiagen will conduct initial research using the CMM’s clinical samples. Based on results from this phase, the CMM may also provide laboratory-based genomics and proteomics services to assist the company in the development and validation of new molecular diagnostic tests.

Besides access to clinical samples, the CMM will also provide molecular analysis capabilities and XenoBase, a software and database system. This bioinformatics platform is capable of analyzing a wide range of molecular and conventional clinical data to help identify clinically actionable associations between diseases, biomarkers, and treatments.

“The speed and analytical depth of XenoBase coupled with the CMM's access to clinical samples can give Qiagen a competitive advantage in the development of new molecular diagnostic tests, especially in the field of oncology,” according to Daniel H. Farkas, Ph.D., executive director of CMM.

Jobs

GEN Jobs powered by HireLifeScience.com connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.

If you have any questions about your subscription, click
hereto email us or call at (914) 740-2189.

You may also be interested in subscribing to the GEN magazine, an indispensable
resource for everyone involved in the business of translating discoveries at the
bench into solutions that fight disease and improve health, agriculture, and the
environment. Subscribe
today to see why over 60,000 biotech professionals read GEN to
keep current in the areas of genomics, proteomics, drug discovery, biomarker discovery,
bioprocessing, molecular diagnostics, collaborations, biotech business trends, and
more.